The monoclonal antibody HC1/6 generated against phorbol 12-myristate 13-acetatetreated U-937 cells recognizes a new cell surface antigen with a broad relative molecu lar mass ranging from 100 to 150 kDa. This antigen is also present on monocytes, platelets and endothelial cells and is weakly expressed by granulocytes. In contrast, it is absent from T, B and erythroblastoid cells. The antigen HC1/6 is also expressed by normal tissue macrophages in tonsil, lung and kidney, as well as in skin biopsies from pathologies such as sarcoidosis and lepromatous leprosy. The expression of the HCl/6 antigen is increased up to 5-fold when U-937 (promonocytic) and HL-60 (myelomonocytic) cell lines are stimulated with phorbol 12-myristate 13-acetate. Con versely, the expression of the HCl/6 antigen is down-regulated in monocytes upon treatment with interferon-y. These findings are discussed in relation with other myeloid cell surface markers. 1 Introduction The differentiation of monocytes is a multistep process charac terized by major changes in their morphological and functional properties [1, 2], These changes can correlate with the reg ulated expression of different cell surface antigens which are useful for the analysis of discrete stages of differentiation. A variety of agents including interferon (IFN)-y, retinoic acid (RA), phorbol 12-myristate 13-acetate (PMA) and 1,25-dihyd roxy vitamin D3 [l,25-(OH)2D3] are able to generate function ally different subpopulations and to regulate the expression of cell surface proteins of the monocytic lineage [3-7]. The exist ence of these subpopulations can be analyzed by using mono clonal antibodies (mAb) specific for surface antigens [8], Thus, CR3 (C D lib or M ol) is mainly present in circulating monocytes and granulocytes, whereas C D llc (pl50,95) is highly expressed in tissue macrophages (M<3>) [9-11]. Also, the expression of CR1 (CD35), CR3 (receptor for C3bi), C D llc and FcRI (CD16) is rapidly increased when cells are treated with certain stimuli such as IFN-y, PMA or the Nformyl-Met-Leu-Phe peptide [9-15].
The promonocytic cell line U-937 and the myelomonocytic cell line HL-60 have often been used to analyze the myeloid differ entiation process [16] [17] [18] . Here, we have used the M«J>-like U-937 cells after differentiation in the presence of PMA as a model system to generate mAb against novel cell surface anti gens of the myeloid family which are up-regulated after differ-
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Preparation of leukocytes
Peripheral blood leukocytes were obtained from heparinized whole venous blood. After elimination of most erythrocytes by gravity sedimentation in the presence of 0.4% dextran, mono-, cytes (Mo) and lymphocytes were separated from granulocytes by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gra dient centrifugation. Granulocytes were obtained from the pellet and separated from contaminant erythrocytes by a 20-s hypotonic lysis in distilled water. Mo were isolated by incubat ing the mononuclear cell fraction in a slightly hypertonic medium followed by a second modified Ficoll-Hypaque density centrifugation [19] , Alternatively, Mo were purified by centrifugal élutriation as described by Figdor et al. [20] . 4 Mo (3 X 106/ml) were incubated at 37 °C, 5% CO2 and 100% humidity in Teflon bags (Jansen's MNL, St. Niklaas, Belgium) in a modified Iscove's medium containing human albumin and supplemented with 2% autologous heat-inactivated serum [21] . After 2 days in culture, Mo were collected from the Tef lon bags, washed, resuspended in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin, 0.02% sodium azide and kept on ice until the detection of surface membrane determinants. Platelets were obtained by density centrifuga tion [20].
Reagents
Recombinant IFN-y (a gift from Dr. Adolf, Boehringer-Ingelheim, Vienna, Austria) was solubilized in RPMI 1640 containing 10% FCS and stored at -20°C , l,25-(OH)2D3 (a gift of Dr. Uskokovic, Hoffmann-La Roche, Nutley, NJ) and RA (Sigma, St. Louis, MO) were stored at -2 0°C in ethanol, PMA (Sigma) was dissolved in dimethylsulfoxide to a concentration of 1 mg/ml. 1374 C. Cabañas, F. Sanchez-Madrid, T. Bellon et al. 
mAb

Production of the hybridoma HCl/6
BALB/c mice were injected i.p. with 15 X 106 PMA-treated U-937 cells on days 48, 33 and i.v. on day 3 prior to fusion. Spleen cells were fused on day 0 with P3-X63Ag8.653 mouse myeloma cells at a 4 :1 ratio according to standard techniques, distributed into 96-well plates (Costar, Cambridge, MA) and grown as described [22] , After 2 weeks, hybridoma culture supernatants were harvested and screened for binding to PMA-differentiated U-937 cells using the 125I-labeled rat antimouse k chain mAb 187.1 as second antibody [28] . The mAb HCl/6 was selected due to its enhanced reactivity for PMAtreated over untreated U-937 cells. This antibody is of the IgGx subclass.
Radiolabeling, immunoprécipitation and electrophoresis
Cells were iodinated using chloroglycoluril (IODO-GEN, Sigma, [29] ) and lysed in PBS, pH 7.4, containing 1% Triton X-100, 1% hemoglobin and 1 mM phenlymethylsulfonyl fluoride. Immunoprécipitation was carried out with protein A-Sepharose (Pharmacia; [22] ) and samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis [30] and autoradiography with enhancing screens [31].
Flow cytometry
Flow cytometry analysis was performed using either an EPICS-C (Coulter Cientificia, Mostoies, Spain) or a FACScan (Becton Dickinson, Mountain View, CA) flow cytometer using logarithmic amplifiers [22] . Specific fluorescence (SF) was obtained by subtracting the peak channel number of the negative control from the peak channel number of the corre sponding experimental sample.
Immunohistochemical staining of human tissue sections
Specimens of human tonsil, thymus, lymph node, brain, lung, skin and kidney were obtained by surgical procedures, Tissue sections were stained by an indirect one-step immunoperoxidase method [22, 32] . For the double immunoperoxidasealkaline phosphatase staining, we followed the sequential method reported by Masson et al. [33] . After the development of the peroxidase reaction, sections were incubated with the second mAb, then with a rabbit anti-mouse IgG, followed by a thhd incubation with the alkaline phosphatase-anti-alkaline phosphatase mAb complex (Dakopatts, Glostrup, Denmark). Each incubation was followed by three washes with Tris saline. Finally, the alkaline phosphatase reaction was developed, yielding a dark blue precipitate which contrasts with the brown colour of the peroxidase reaction. Sections were mounted in buffered gelatin for microscopic examination.
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Effect of several differentiation agents on the expression of the antigen recognized by the mAb HCl/6
The mAb HCl/6 was obtained by immunization with PMAtreated U-937 cells. The antigen recognized by HCl/6 is mod* erately expressed on untreated U-937 cells, but its expression is strongly increased after PMA-induced differentiation (Fig. 1) . IFN-y, l,25-(OH)2D3 and RA were also used to induce differentiation of U-937 cells and the expression of HCl/6 and several other cell surface markers was analyzed by flow cytometry (Fig. 1) . Other cell types were also assayed for reactivity with the mAb HC1/6 (Fig. 2 
), No staining was found with the erythroblastoid cell line K-562 nor with the lymphoblastoid B cell line JY and the T cell line JM. Similarly, a very weak reactivity was found with the T cell leukemic line Jurkat. In addition, granulocytes
were weakly labeled by the mAb HC1/6, whereas peripheral blood Mo and platelets were clearly positive as opposed to the negative staining of lymphocytes. The relatively restricted expression of this antigen to cells of the myeloid lineage (U-937, HL-60, Mo and platelets) becomes also apparent after study of different cell types treated with PMA (Fig. 2) . Only the promonocytic cell line U-937 and the myelomonocytic cell line HL-60 showed an increased expression of the antigen in response to PMA. This contrasts with the negative response of T, B and erythroblastoid cell lines.
As determined by immunoprécipitation analysis under reduc ing conditions, a broad band of 100-150 kDa was recognized by the mAb HC1/6 from cell surface radioiodinated U-937 cells after differentiation in the presence of PMA (Fig. 3, lane 2) . The same relative molecular mass (Mr) was obtained under nonreducing conditions (lane 4) demonstrating the absence of interchain disulfide bonds. The CDllc/CD18 antigen complex was also immunoprecipitated for comparative purposes (lane 3).
Detection of the antigen recognized by the mAb HC1/6 in tissue MO
The antigen recognized by the mAb HC1/6 was visualized by immunoperoxidase staining of frozen tissue sections. Thus, MO from tonsil, lung and kidney were labeled by the mAb HC1/6 (Fig. 4) . Scattered macrophages in the paracortical area (T cell zone) from tonsil (A), alveolar MO from lung (C) and mesangial MO from kidney glomeruli (B) were positively stained with mAb HC1/6. In addition, Kupffer cells from liver as well as MO from lymph node and thymus were labeled by mAb HC1/6, whereas microglial cells and dendritic epidermal cells were negative (data not shown). In most of these tissues, the presence of the HC1/6 antigen was evident in endothelial cells. Since the C D llc antigen is an excellent marker for tissue MO, we carried out a double staining with HC1/6 and anti-CD 11c mAb (D). As shown by immunoperoxidase/alkaline phosphatase staining, the C D llc (brown) and HC1/6 (dark blue) antigens are co-expressed by the majority of MO. How ever, the HC1/6 antigen was expressed on vascular structures whereas the C D llc antigen was not.
Different pathologies characterized by the presence of an increased number of activated MO were also analyzed by staining of skin sections with the mAb HC1/6. In lepromatous leprosy and sarcoidosis, most of the infiltrating MO, as well as the epithelioid and giant cells present in the granulomas ex pressed the HC1/6 antigen (data not shown).
Discussion
The mAb HC1/6 described here recognizes a protein with a broad Mr ranging from 100 to 150 kDa and which seems to be specific for the myeloid lineage. This antigen is highly ex pressed on peripheral blood Mo, tissue MO, platelets, endothelial cells and, upon differentiation, on the MO-like U-937 and HL-60 cells.
The expression of the antigen HC1/6 on Mo is not due to activation during the isolation protocol [37] , since the same results were obtained when Mo were purified by the countercurrent elutriation method [20] . Other myeloid antigens with a similar Mr as HC1/6 but differ ent characteristics have been described [8, 9, 38, 39] . Thus, the antigens C D llb and C D llc are associated with a second |3 subunit (CD18) and are not present on peripheral platelets, as opposed to HC1/6. On the other hand, mAb of the CD13 cluster which are specific for a 150-kDa protein, differ from the antigen HC1/6 in their strong reactivity for bile canaliculi and granulocytes, the lack of staining of platelets and the dis tinct behavior upon stimulation with different agents (Fig. 1) , Moreover, the CD31 antigen (sharp band at 130 kDa), although present on platelets,is highly expressed by peripheral granulocytes as well as by the T cell lines Jurkat and CEM as opposed to the antigen HC1/6 (broad band at 100-150 kDa).
A review of other unclustered antigens reveals that none is identical to the HC1/6 antigen. The |3 subunit of the VLA complex (110 kDa unreduced, 130 kDa reduced) which is identical to the gplla [30] , is also present in platelets. How ever, this antigen is different from HC1/6 since: (a) the Mr of gplla changes between reducing or nonreducing conditions and (b) mAb directed against this antigen strongly react with the erythroblastoid cell line K-562 [41, 42] . Moreover, mAb MoU26, which recognizes a 130-140-kDa antigen [38] is dis tinct from the mAb HC1/6 due to the differential cellular reac tivity since MoU26 strongly labels K-562 and does not react with Mo. Finally, the mAb CLB-HEC-75, which recognizes a 150-kDa antigen present on platelets and endothelial cells, is absent from Mo [43] and does not compete with the mAb HC1/6 for binding to PMA-treated U-937 cells (data not shown).
The mAb HC1/6 reacts with most of the vessels (venules, veins, small arteries and capillaries) and specially with high endothelial venules. Similarly, the ICAM-1 antigen and other members of the integrin superfamily are also expressed by endothelial cells [44] . Interestingly, the ICAM-1 antigen (ligand for LFA-1 antigen) is also up-regulated by PMA in U-937 and HL-60 ceils [45 , 46] . Since the antigens of the inte grin family are involved in cell-matrix and cell-cell interac tions, a similar function could be suggested for the antigen HC1/6, However, we have been unable to assign any func tional role to the antigen HC1/6. In our hands, adhesion, mig ration antigen presentation and antibody-dependent cellmediated cytotoxicity of Mo are unaffected by the presence of the mAb HC1/6. The fact that this antigen is not only present on Mo/MO but also in platelets, suggests that the function of the antigen HC1/6 is shared by both lineages.
